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ABSTRACT
Objective The introduction of anti tumour necrosis
factor-α (anti-TNFα) therapy might impact healthcare
expenditures, but there are limited data regarding the
costs of inflammatory bowel diseases (IBD) following the
introduction of these drugs. We aimed to assess the
healthcare costs and productivity losses in a large cohort
of IBD patients.
Design Crohn’s disease (CD) and ulcerative colitis (UC)
patients from seven university hospitals and seven
general hospitals were invited to fill-out a web-based
questionnaire. Cost items were derived from a 3 month
follow-up questionnaire and categorised in outpatient
clinic, diagnostics, medication, surgery and
hospitalisation. Productivity losses included sick leave of
paid and unpaid work. Costs were expressed as mean 3-
month costs per patients with a 95% CI obtained using
non-parametric bootstrapping.
Results A total of 1315 CD patients and 937 UC
patients were included. Healthcare costs were almost
three times higher in CD as compared with UC, €1625
(95% CI €1476 to €1775) versus €595 (95% CI €505
to €685), respectively (p<0.01). Anti-TNFα use was the
main costs driver, accounting for 64% and 31% of the
total cost in CD and UC. Hospitalisation and surgery
together accounted for 19% and <1% of the healthcare
costs in CD and 23% and 1% in UC, respectively.
Productivity losses accounted for 16% and 39% of the
total costs in CD and UC.
Conclusions We showed that healthcare costs are
mainly driven by medication costs, most importantly by
anti-TNFα therapy. Hospitalisation and surgery
accounted only for a minor part of the healthcare costs.
INTRODUCTION
Inflammatory bowel disease (IBD), comprising
Crohn’s disease (CD) and ulcerative colitis (UC), is
characterised by a chronic relapsing intestinal
inflammation that may lead to severe complications
and disability. As there is no curative treatment,
Significance of this study
What is already known on this subject?
▸ Inflammatory bowel disease (IBD) is associated
with a high economic burden to society.
▸ In cost-of-illness studies conducted in the
prebiological era, over half of the healthcare
costs were driven by surgical and medical
hospitalisation.
▸ In the prebiological era, productivity losses due
to decreased work productivity accounted for
approximately 50% of the total costs in Europe.
What are the new findings?
▸ This is the first cost-of-illness study in IBD
following the introduction of infliximab and
adalimumab in a large patient cohort, analysing
both healthcare costs and productivity losses.
▸ The traditional cost profile has changed and
healthcare costs are now mainly driven by
medication use, in particular antitumour
necrosis factor-α (anti-TNFα) therapy.
▸ Surgery and hospitalisation accounted for only
19% and <1% of the healthcare costs in
Crohn’s disease (CD) patients and 23% and 1%
in ulcerative colitis (UC) patients.
▸ Productivity losses due to sick leave accounted
for 16% of the total costs in CD and 39% of
the total costs in UC.
How might it impact on clinical practice in
the foreseeable future?
▸ By identifying and quantifying the relative
contribution of different resources to the overall
healthcare and productivity losses, this study
provides important insights into the economic
burden of IBD on the society in this era of
widespread anti-TNFα therapy use. This is
relevant for healthcare providers, policy makers
and clinicians.
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most patients need life-long drug treatment and many will face
surgery.1 Consequently, IBD is associated with a high economic
burden to society, in which hospitalisation and surgery account
for more than half of the healthcare costs.2–4 Moreover, due to
its early onset and chronic character, IBD profoundly affects
work productivity with productivity losses resulting from sick
leave and work disability amounting to almost 50% of the total
costs.2 3 5–7
In the current era of escalating healthcare costs and growing
constraints on healthcare budgets, there is a need for more
accurate information regarding costs of chronic diseases. Most
cost-of-illness studies in IBD have been performed before the
introduction of the highly effective, but expensive biological
therapies and can therefore be considered outdated.2–4 7 It has
been suggested that costs of antitumour necrosis factor-α
(anti-TNFα) therapy are being offset by a reduction in surgery
and hospitalisation rates on the one hand,8–11 and increased
work productivity on the other,12–14 but accurate data on total
costs in Europe are presently lacking.
To address these issues, we recently initiated the ‘Costs Of
Inflammatory bowel disease in the Netherlands’ or ‘COIN’
study in order to (1) estimate the total healthcare and productiv-
ity losses in a large cohort of IBD patient attending both univer-




In The Netherlands, most patients with an established diagnosis
of IBD and need for medical or surgical therapy are treated in
university hospitals or general hospitals. We identified CD
patients and UC patients using the diagnosis treatment combina-
tions (DTCs) for respectively CD and UC. DTCs are based on
the International Classification of Disease, Ninth Revision.15 16
DTCs were introduced in 2005 and can be considered the
Dutch version of the Diagnosis Related Groups as used in other
countries, for example, the USA. DTCs form the basis to pay
inpatient services provided by hospitals and physicians. DTCs
have been used to identify IBD patients in The Netherlands pre-
viously and have been found to be useful and reliable in this
respect.17 18 All patients from seven university medical centres
and seven general hospitals aged 18 years or older were eligible
for participation. The study was centrally approved by the ethics
committee of the University Medical Centre Utrecht.
Web-based questionnaire
We developed a secure web-based questionnaire and participants
were provided with a unique username and password combin-
ation. Patients were invited to enter the username and
password-secured and firewall-protected website and were asked
to fill out the questionnaires. After completing the baseline
questionnaire, patients received an invitation to fill out the
3-month follow-up questionnaire and an email reminder
2 weeks after the initial invitation.
Demographic and disease characteristics
The baseline questionnaire included questions on demographics
(gender, age, smoking habits and education) and disease charac-
teristics. Education was categorised as low education (no educa-
tion, primary education, secondary education and technical or
professional school) or high education (higher vocational educa-
tion and university). Disease characteristics included type of
IBD, year of diagnosis, disease localisation, penetrating disease
course, abdominal surgery in the past and self-reported disease
activity. Patients in whom medical treatment was initiated or
changed or who received IBD-related surgery were considered
to have active disease.
Healthcare utilisation
We obtained information on resource utilisation from the
3-month follow-up questionnaire. IBD-related resource utilisa-
tion within healthcare was categorised under the following sub-
groups: (1) outpatient clinic, including the number of outpatient
physician consultations (eg, gastroenterologist, internist, surgeon
and rheumatologist), visits to IBD or stoma nurses and dieti-
cians, visits at the emergency department and visits to the
general practitioner; (2) diagnostic procedures including number
and type of endoscopies, radiological procedures and blood
tests; (3) medication use, which included all IBD-specific drug
use such as mesalazine, corticosteroids, immunomodulators and
anti-TNFα therapies. The mean number of daily doses over the
3-month time frame was estimated. We assumed that all main-
tenance therapies were used without interruption over the study
period; (4) hospitalisation, defined as the number of days hospi-
talised, including number of days at the intensive care unit; and
(5) type of IBD-related surgery.
Productivity losses
Productivity losses (also referred to as ‘indirect (non-healthcare)
costs’) refer to the costs associated with lost or impaired ability
to work of paid and unpaid (voluntary) work. To assess product-
ivity losses we used sick leave (absenteeism) of patients and
their caregivers as outcome measurement. Patients were asked
which of the following situations applied best to their situation:
being employed, fully or partially disabled, retired or early
retired, homemaker, student or unemployed. Employed patients
or partially disabled patients with a paid job indicated the
number of work hours and number of workdays per week.
Patients were asked to report the number of sick leave days
from both paid and unpaid (voluntary work) work within the
previous 3 months. Additionally patients were asked to report
whether caregivers were absent from paid work in order to take
care of them, and for how many days. For caregivers we
assumed an average work day of 6.28 h, based on data from the
Statistics Netherlands.19
Out-of-pocket costs
Patients were asked to report IBD-related out-of-pocket costs
within the previous 3 months. These expenditures included
patient’s deductibles for healthcare insurance, travel costs and
over-the-counter drug use (eg, antidiarrhoeals, analgesics and
vitamins).
Calculation of costs
We performed a cost-of-illness study from a societal perspective.
For each patient, costs were calculated by multiplying units of
resource utilisation as reported by the patients by their unit
costs. Reference prices are listed in online supplementary appen-
dix 1. Costs are expressed per 3 months in 2011 Euros, using
Dutch consumer price indices where appropriate. Discounting
was not applied as all costs were made within the same year. As
practice patterns and the patient case mix may vary between
university medical centres and general hospitals, we compared
healthcare costs between university and general hospitals. The
number of days patients and caregivers were absent from paid
or unpaid work due to sick leave over 3 months could not
exceed 65 days (weekends days were excluded) and were valued
using age- and sex-specific productivity losses.20 Out-of-pocket
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costs were calculated according to patient specifications, and
where necessary updated to 2011 Euros. In order to provide
decision makers with explicit information, and allow
health-economic analyses from different perspectives (ie, soci-
etal vs healthcare-payer perspective), costs are presented accord-
ing to the classification of Drummond et al, that is, healthcare
costs, productivity losses and patient costs.21
Non-responders
To control equality between the study population (responders)
and the patients who did not respond (non-responders), we per-
formed a non-responder study. All non-responders from one
participating centre (n=685) were sampled to assess the demo-
graphic (age, gender) and disease characteristics (disease dur-
ation, penetrating disease course and abdominal surgery in the
past) of a subset of the non-responders. The demographic and
disease characteristics between the responders and the non-
responders were compared.
Statistical analysis
Data analysis was performed using SPSS V.18.0. Descriptive sta-
tistics were used to characterise patients with CD and UC. We
reported means with an SD and medians with an IQR.
Comparisons between CD and UC patients were analysed with
Student t test for continuous variables and χ2 for dichotomous
variables. To compare disease duration between CD and UC
patients, the Mann–Whitney U test was used. To increase trans-
parency, all unit costs are stated in online supplementary appen-
dix 1 and frequency tables of resource utilisation are displayed.
Despite the skewed nature of cost data, we reported mean
patient costs, as overall total costs—which matters most—can
then be calculated. Costs were expressed as mean costs with
95% CI estimated using non-parametric bootstrap sampling. To
compare costs between the general hospitals and university
medical centres, the Mann–Whitney U test was used. To identify
independent predictors of high healthcare costs, we included
demographic and disease-specific characteristics associated with




Figure 1 shows the study flowchart. In total 2252 patients were
included in the cost analysis.
Table 1 presents the demographic and disease characteristics
of the CD (n=1315) and UC (n=937) study population.
Distinction was made based on self-reported type of IBD.
Patients who did not know their type of IBD, reported UC with
disease localisation in the ileum or reported UC with fistulas
were excluded from the cost analysis and categorised as
IBD-unspecified (n=324, 13%).
Online supplementary appendix 2 shows data on gender, age,
disease duration, penetrating disease course and previous
abdominal surgery in both the responders (CD: n=1315 and
UC: n=937) and a subset of non-responders (CD: n=405 and
UC: n=247). There were no relevant statistical significant differ-
ences between these groups.
Figure 1 Study flowchart. CD,
Crohn’s disease; IBD, inflammatory
bowel disease; UC, ulcerative colitis.
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Healthcare costs
The mean healthcare costs per CD patients per 3 months were
€1625 (95% CI €1476 to €1775). With a mean of €1145 (95%
CI €1042 to €1249), medication costs were the major cost
driver of healthcare costs (71% of healthcare costs). Of the CD
patients, 297 (23%) were on anti-TNFα therapy, accounting for
64% of the healthcare costs in this 3-month intercept.
Hospitalisation and surgery accounted for 19% and <1% of the
healthcare costs, respectively. The relative contribution of each
cost item or service category as a proportion of the total health-
care costs is summarised in table 2.
The components of resource utilisation and healthcare costs
of UC patients are presented in table 3.
The mean healthcare costs over 3 months for UC were signifi-
cantly lower as compared with CD, namely, €595 (95% CI
€505 to €685), p<0.01. Again, with 59% of the healthcare
costs, the main cost driver was medication use. In UC, mesala-
zine (€136; 95% CI €130 to €143) and anti-TNFα therapy
(€187; 95% CI €128 to €246) together accounted for over half
of the healthcare costs (54%), with 602 (64%) patients treated
with mesalazine and 37 (4%) with anti-TNFα therapy.
There were no statistically significant differences in healthcare
costs of CD and UC patients between university medical centres
and general hospitals, as shown in figure 2. The top 10% high-
cost patients accounted for 40% of the healthcare costs in CD
and 59% in UC. In CD, factors associated with high healthcare
costs were current flares (adjusted (adj.) OR 4.00; 95% CI 2.74
to 5.82) and penetrating disease course (adj. OR 2.30; 95% CI
1.54 to 3.44). In UC patients, self-reported flares (adj. OR 2.35;
95% CI 2.50 to 3.68) and current ileostomy (adj. OR 2.35;
95% CI 1.06 to 5.23) were associated with top 10% high-cost
patients.
Productivity losses
A total of 705 (54%) CD and 573 (61%) UC patients were cur-
rently employed. Of all CD patients currently employed, 18%
reported sick leave with a mean loss of employment days of 2.5
(95% CI 1.8 to 3.4), translating in a mean loss of earnings of
€289 (95% CI €198 to €379) over 3 months (table 4). In UC
patients, 13% were absent from work due to sick leave with a
mean loss of work days of 2.5 (95% CI 1.6 to 3.4), with asso-
ciated loss-of-productivity of €362 (95% CI €231 to €493);
p<0.01. Total productivity losses were €326 (95% CI €234 to
€418) in CD and €395 (95% CI €261 to €529) in UC (table 4).
Out-of-pocket costs
Out-of-pocket costs were €75 (95% CI €65 to €84) in CD and
€57 (95% CI €49 to €66) in UC. According to patient specifica-
tions, most expenditure was on deductibles of healthcare insur-
ance, vitamins and other over-the-counter expenditures, and
memberships of patient associations.
Total costs
The total costs (healthcare costs+productivity costs
+out-of-pocket costs) were €2001 (95% CI €1808 to €2194)
for CD patients and €1023 (95% CI €838 to €1208) for UC
patients. Productivity costs accounted for 16% of the total costs
in CD patients and 39% in UC patients. Out-of-pocket costs
accounted for <1% of the total costs in both patient groups.
DISCUSSION
This study provides the most comprehensive update on the cost
profile of IBD since the introduction and expanding use of
anti-TNFα therapy in Europe. Up to the 2000s, hospitalisation
and surgery were the major cost drivers in IBD. We report that
nowadays medication use, anti-TNFα in particular, represents
the main source of healthcare costs while costs related to hospi-
talisation and surgery are substantially reduced as compared
with previous studies.2–4
Interestingly, total healthcare costs in IBD patients over time
do not seem to increase. Extrapolating the 3-month healthcare
costs from our study towards annual costs yielded mean costs of
€6501 and €2380 per year in CD and UC patients. A cross-
sectional, single centre study conducted in the UK, with an
almost similar study population, reported 6-month healthcare
costs of £1652 and £1256 in CD and UC patients for the year
2004.2 Extrapolating these costs to a 1-year period, and using
UK consumer price index to inflate (1.23) and convert (1£=
€1.56 on 1 December 2011) these costs to 2011 Euros would
equal €6338 for CD and €4819 for UC. In this study, medical
and surgical hospitalisation contributed to over half of total
costs, but only 18% of healthcare costs in CD and 24% in UC
was due to direct medication expenditure. This contrasts with
data from our study, in which medication costs accounted for
up to 71% and 59% of the healthcare costs for CD and UC,
respectively. Results from a large European cohort study by
Odes et al4 were in line with the UK study. They reported that
over half of the healthcare costs were due to hospitalisation and
surgery, while only 30% of total costs were due to medication
use, with mesalazine being the most expensive drug.4 The same
cost profile was reported in a hospital-based nationwide Spanish
study conducted in 1997 in which medical and surgical hospital-
isation accounted for 53% of the healthcare costs.3
Table 1 Demographic and disease characteristics of the study
participants
CD n=1315 UC n=937 p Value
Male gender (%) 490 (37.3) 482 (51.4) <0.01
Age—years (±SD) 47.8 (13.6) 49.8 (13.3) <0.01
Smoking (%) <0.01
Current 265 (20.2) 77 (8.2)
Never 672 (51.1) 542 (57.8)
Ex-smoker 378 (28.7) 318 (33.9)
Disease duration—median (IQR) 16.2 (8.3–26.3) 13.3 (6.6–21.5) <0.01
Disease localisation (%) NA
Large bowel 369 (28.1) 937 (100)
Small bowel 260 (19.7) NA
Both small and large bowel 647 (49.2) NA
Unknown 39 (3.0) NA
Penetrating disease course (%) 693 (52.7) NA NA
Disease in remission (%) 1035 (78.7) 699 (74.6) 0.03
Abdominal surgery in the past
(%)
717 (54.4) 171 (18.2) <0.01
Stoma (%) 159 (12.1) 53 (5.7) <0.01
Low education (%) 821 (62.4) 543 (58.0) <0.03
Employment status (18–
65 years) (%)
1177 (89.5) 816 (87.1) <0.01
Employed 705 (53.6) 573 (61.2)
Fully work disabled 206 (17.5) 80 (9.8)
Partial work disabled 98 (8.3) 40 (4.9)
Retired 52 (4.4) 37 (4.5)
Homemaker 111 (9.4) 62 (7.6)
Student 44 (3.7) 12 (1.5)
CD, Crohn’s disease; UC, ulcerative colitis.
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Even though healthcare costs between the USA and Europe
differ to a large extent, comparable trends in treatment para-
digms should have induced the same alterations in cost profiles
as observed in our study. Kappelman et al studied healthcare
costs using medical and pharmacy claims from an administrative
database between 2003 and 2004, in which 10% of all CD
patients had at least two claims of infliximab infusions.22 In this
study, pharmaceutical claims accounted for the largest propor-
tion of healthcare costs (35%), in which infliximab was the most
costly medication. But none of the cost studies in the past have
taken the economic impact of adalimumab into account, as this
agent was registered only in 2007 for CD. Thus, it seems that
there is a shift in cost profile from surgery and hospitalisation
towards anti-TNFα treatment. Apparently, the high costs of
these drugs are partly compensated for by a significant reduction
of surgery and hospitalisation rates. Obviously, a longer
follow-up period of 2–5 years is needed to confirm this trend.
Recent published reviews and cohort studies, however, showed
a decrease in surgery and hospitalisation rates as well, under-
scoring our findings.11 23 A similar development has been
reported in the treatment of rheumatoid arthritis, with a decline
in surgery rates since the introduction of anti-TNFα therapy for
this indication.9 24–26
We also examined productivity losses due to IBD-related sick
leave, accounting for 16% of total costs in CD and 39% in UC.
Comparisons between this study and older studies are limited




per patient (95% CI)
Mean healthcare costs per 3 months per




Gastroenterologist 588 (44.7) 0.56 (0.03 to 0.07) 60.65 (54.70 to 66.59) 3.7
Specialised nurse 255 (19.4) 0.19 (0.15 to 0.22) 5.67 (4.86 to 6.47) 0.3
Internist 64 (4.9) 0.06 (0.04 to 0.08) 5.61 (3.66 to 6.66) 0.3
Dietician 47 (3.6) 0.07 (0.05 to 0.09) 3.52 (2.33 to 4.70) 0.2
Surgeon 36 (2.7) 0.06 (0.03 to 0.08) 6.24 (3.71 to 8.78) 0.4
Rheumatologist 36 (2.7) 0.04 (0.02 to 0.05) 4.06 (2.62 to 5.50) 0.2
Dermatologist 25 (1.9) 0.03 (0.02 to 0.04) 3.50 (1.90 to 5.11) 0.2
Occupational physician 19 (1.4) 0.02 (0.01 to 0.03) 1.88 (0.87 to 2.88) 0.1
Psychiatrist 9 (0.7) 0.06 (−0.4 to 0.15) 7.68 (−5.12 to 20.47) 0.5
Emergency room 39 (3.0) 0.04 (0.03 to 0.05) 5.83 (3.73 to 7.94) 0.4
General practitioner during
day-time
4.95 (3.82 to 6.09) 0.3
Visit 111 (8.4) 0.16 (0.12 to 0.19)
Home visit 8 (0.6) 0.01 (0.00 to 0.02)
General practitioner (during
night/weekend-time)
Visit 68 (5.2) 0.09 (0.06 to 0.06) 4.99 (3.85 to 6.13) 0.3
Home visit 8 (0.6) 0.01 (0.00 to 0.01)
Subtotal 114.12 (97.35 to 130.89) 6.9
Diagnostics procedures
Laboratory 155 (11.8) 0.23 (0.17 to 0.29) 4.18 (3.08 to 5.27) 0.3
Colonoscopy 90 (6.8) 0.07 (0.06 to 0.09) 24.31 (19.71 to 29.46) 1.5
MRI scan 40 (3.1) 0.03 (0.05 to 0.17) 5.86 (3.96 to 7.76) 0.4
CT scan 27 (2.1) 0.02 (0.01 to 0.04) 3.61 (1.72 to 5.49) 0.2
Abdominal x-ray 13 (1.0) 0.01 (0.00 to 0.01) 0.36 (0.15 to 0.58) 0.0
Ultrasonography 36 (2.7) 0.03 (0.02 to 0.04) 1.03 (0.62 to 1.44) 0.1
DXA scan 22 (1.7) 0.01 (0.01 to 0.02) 1.22 (0.68 to 1.77) 0.1
Subtotal 40.60 (33.58 to 47.56) 2.6
Medication use
Mesalazine 292 (22.2) NA 54.82 (49.27 to 60.38) 3.4
Budesonide 75 (5.7) NA 10.83 (8.44 to 13.21) 0.7
Prednison 35 (2.7) NA 0.40 (0.27 to 0.53) 0.0
Azathioprine 338 (25.7) NA 23.30 (21.15 to 25.44) 1.4
6-Mercaptopurine 89 (6.8) NA 6.13 (4.90 to 7.37) 0.4
Methotrexate 43 (3.3) NA 8.12 (5.73 to 10.52) 0.5
Infliximab 137 (10.4) NA 490.84 (411.65 to 570.03) 30.2
Adalimumab 166 (12.3) NA 550.89 (427.46 to 629.33) 33.9
Subtotal 1145.33 (1041.80 to 1248.86) 70.5
Hospitalisation 60 (4.6) 10 (2 to 19)* 315.25 (231.18 to 399.33) 19.4
Surgery 12 (0.9) NA 9.90 (2.71 to 17.10) 0.6
Total healthcare costs 1625.18 (1475.87 to 1774.50) 100.0
*Mean number of days hospitalised (range).
CD, Crohn’s disease; DXA, Dual-emission x-ray absorptiometry.
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due to varying methodologies in measurement and valuation of
productivity losses, as well as differences in social security pol-
icies. We therefore focused on sick leave in days to illustrate
changes in productivity losses. We found that 18% of employed
CD patients and 13% of employed UC patients reported sick
leave in the previous 3 months. Previous studies found that
14%–50% of CD patients and 15%–32% of UC patients
reported sick leave.2 3 727 Higher age was found to be an inde-
pendent predictor of sick leave.27 Although patients from our
study cohort were older with longer disease duration as




per patient (95% CI)
Mean healthcare costs





Gastroenterologist 347 (37.0) 0.41 (0.36 to 0.46) 41.06 (36.22 to 45.90) 6.9
Specialised nurse 133 (14.2) 0.13 (0.09 to 0.16) 3.76 (2.97 to 4.56) 1.0
Internist 40 (4.3) 0.05 (0.03 to 0.07) 4.26 (2.57 to 5.95) 0.7
Dietician 30 (3.2) 0.05 (0.03 to 0.07) 2.34 (1.39 to 3.28) 0.4
Surgeon 16 (1.7) 0.03 (0.01 to 0.04) 3.06 (1.40 to 4.72) 0.5
Rheumatologist 8 (0.9) 0.04 (0.02 to 0.05) 1.28 (0.30 to 2.27) 0.2
Dermatologist 8 (0.9) 0.01 (0.00 to 0.03) 1.71 (−0.13 to 3.43) 0.3
Occupational physician 5 (0.5) 0.01 (0.00 to 0.02) 1.07 (−0.09 to 2.23) 0.2
Psychiatrist 2 (0.2) 0.00 (0.00 to 0.01) 0.36 (−0.15 to 0.86) 0.1
Emergency room 15 (1.6) 0.02 (0.01 to 0.03) 2.67 (1.14 to 4.20) 0.4
General practitioner (during day-time)
Visit 52 (5.5) 0.08 (0.06 to 0.11) 2.48 (1.71 to 3.25) 0.4
Home visit 2 (0.2) 0.01 (0.00 to 0.02)
General practitioner (during night/weekend-time)
Visit 42 (4.5) 0.07 (0.04 to 0.09) 4.33 (3.11 to 5.55) 0.7
Home visit 5 (0.5) 0.01 (0.00 to 0.01)
Subtotal 68.38 (60.48 to 76 to 29) 11.4
Diagnostics procedures
Laboratory 57 (6.1) 0.11 (0.05 to 0.17) 1.95 (0.89 to 3.00) 0.3
Colonoscopy 66 (7.0) 0.07 (0.05 to 0.09) 24.31(18.22 to 30.22) 4.1
MRI scan 7 (0.7) 0.01 (0.00 to 0.02) 1.60 (0.36 to 2.85) 0.3
CT scan 5 (0.5) 0.01 (0.00 to 0.01) 0.82 (0.10 to 1.53) 0.1
Abdominal x-ray 5 (0.5) 0.01 (−0.00 to 0.03) 0.42 (−0.15 to 0.98) 0.1
Ultrasonography 12 (1.3) 0.01 (0.00 to 0.02) 0.40 (0.15 to 0.65) 0.1
DXA scan 7 (0.7) 0.01 (0.00 to 0.01) 0.45 (0.06 to 0.85) 0.1
Subtotal 29.85 (22.97 to 36.73) 5.1
Medication use
Mesalazine 602 (64.2) NA 136.47 (129.9 to 143.01) 22.9
Budesonide 24 (2.6) NA 4.86 (2.93 to 6.79) 0.8
Prednison 24 (2.6) NA 0.39 (0.23 to 0.54) 0.1
Azathioprine 143 (15.3) NA 13.83 (11.74 to 15.92) 2.3
6-Mercaptopurine 57 (6.1) NA 5.51 (4.12 to 6.90) 0.9
Methotrexate 7 (0.7) NA 1.86 (0.48 to 3.23) 0.3
Infliximab 28 (3.0) NA 145.02 (92.02 to 198.02) 24.4
Adalimumab 9 (1.0) NA 41.92 (14.61 to 69.22) 7.0
Subtotal 349.86 (290.86 to 409.58) 58.8
Hospitalisation 25 (2.7) 11 (2 to 19)* 138.64 (83.85 to 193.42) 23.3
Surgery 5 (0.5) NA 8.16 (0.78 to 15.54) 1.4
Total health care costs 594.89 (504.90 to 684.89) 100.0
*Mean number of days hospitalised (range).
DXA, Dual-emission x-ray absorptiometry; UC, ulcerative colitis.
Figure 2 Comparison of distribution
of healthcare costs between university
medical centres and general hospitals.
CD, Crohn’s disease; UC, ulcerative
colitis.
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previously reported, we found similar or even lower rates of
sick leave. We did not incorporate productivity losses due to
work disability, as we did not know the cause of work disability.
Inclusion of these costs would have therefore overestimated the
total productivity costs. From literature, however, we know that
the impact of work disability is considerable. A German study
employing a 4-week diary reported that 49% of the total costs
were due to work disability in CD and 32% in UC, respect-
ively.7 Similarly, a Swedish study reported that 36% of the total
costs of IBD were due to work disability.5 Finally, we did not
include productivity losses while at work due to the disease
(presenteeism). At this point, there are no validated question-
naires to assess presenteeism with a longer recall time than
7 days. Therefore we might have underestimated the productiv-
ity losses.
The strengths of this study included both the size and the
diversity of the case mix by including patients from both univer-
sity and general hospitals throughout The Netherlands. In order
to enrol a large number of patients, we opted for the present
web-based design. An inherent limitation of such a strategy is
sampling bias. Although internet access among IBD patients has
been reported to be high and The Netherlands has a very high
internet penetration of 89%,28 our sample is not necessarily
representative of the IBD population as a whole. It was expected
that relatively few elderly subjects would participate, but we did
recruit a total of 302 (10%) patients over the age of 65.
In general, participation rates for single questionnaires can be
expected to be higher. However, we asked patients to participate
in a longitudinal cohort study, possibly explaining the lower par-
ticipation rate. We assessed the representativeness of our study
by performing a non-responder study and could not detect
major differences in demographic and disease characteristics
between responders and non-responders. Reassuringly, we were
able to confirm previously reported outcome data, supporting
the internal validity of our cohort. For example, prior studies
found slightly more frequently UC in men, whereas CD occurs
20%–30% more frequently in women,29–31 as we found in our
study. Furthermore, we found comparable rates of abdominal
surgery of 54% in CD patients and 18% in UC patients as previ-
ously reported.23 32 Additionally, over 10% of the CD patients
will eventually require permanent faecal diversion,32 similar to
the 12% reported in our population. Finally, during disease
course, the cumulative risk for perianal involvement was
50%,32 33 comparable with the 53% of reported penetrating
disease course in our CD population. As such, in spite of poten-
tial limitations, we believe that our study provides reliable and
generalisable data on total costs in IBD.
It could well be possible that due to the relatively short obser-
vation period healthcare costs have skewed in favour of the
medical costs. However, we have chosen to set a strict time limit
for the observation period, as it is known from previous studies
that the reliability of productivity and healthcare data is decreas-
ing if the recall times exceed more than 3 months. Our large
study size, however, provides a substantial cumulative observa-
tion time of nearly 600 patient years.
Our study provides valuable information which, if interpreted
with caution, can be used for theoretical modelling and cost-
effectiveness studies, and aids to put the high costs of anti-TNF
drugs into perspective. Its selective use could lead to a reduction
of hospitalisation and surgery rates and in an increase in work
productivity thereby rendering these drugs cost-effective. In
conclusion, this is the first cost-of-illness study since the intro-
duction of anti-TNF therapy in Europe. Total costs do not seem
to increase, but cost profiles have changed markedly. Healthcare
costs are now mainly driven by medication costs.
Hospitalisation and surgery did only account for small percen-
tages of healthcare costs.
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